NICE has rejected the use of AstraZeneca and Daiichi Sankyo’s Enhertu as an NHS treatment for advanced HER2-low breast cancer, a decision that the companies have described as “devastating”.
AstraZeneca AZN and partner Daiichi Sankyo announced that the FDA has approved the supplemental biologics license application (sBLA) seeking approval for expanded use of Enhertu (trastuzumab ...
Also Read: AstraZeneca To Pump $570 Million Into Canada, Driving Expansion, Job Growth In the trial, Enhertu showed a 36% reduction in the risk of disease progression or death versus chemotherapy ...
The illegal importation case may not stop there, AstraZeneca CEO Pascal Soriot warned. “It’s possible that a similar issue is raised around Enhertu,” Soriot told reporters Thursday.
Also Read: FDA Approves AstraZeneca, Daiichi Sankyo's Enhertu For Certain Type Of Breast Cancer Patients The U.K. Treasury, under the direction of Rachel Reeves, is reportedly considering ...
Enhertu, an oncology drug by AstraZeneca, led new drug sales in 2024 with Rs 58 crore, reflecting rising cancer cases. Over 3 ...
Learn more about whether AstraZeneca PLC or Intra-Cellular Therapies, Inc. is a better investment based on AAII's A+ Investor ...
AstraZeneca AZN stock has risen 8.6% in the past month, mainly due to mixed fourth-quarter results and a positive update from ...
New York State Common Retirement Fund grew its position in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 7.4% during the 4th ...
Among the newly launched brands, the gastro segment recorded the highest sales at Rs 167 crore from 394 brands. The ...